---
title: "JUMPCAN: Received the acceptance notice for the pediatric constipation granules medication"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247445687.md"
description: "JUMPCAN announced that its wholly-owned subsidiary, Jichuan Co., Ltd., has received the \"Acceptance Notice\" for the listing application of \"Children's Bian Tong Granules\" issued by the National Medical Products Administration. This drug is classified as Traditional Chinese Medicine Category 1.1 and is used for pediatric constipation, with the prescription having applied for a patent. Currently, there are no drugs with the same prescription listed or registered in China. The project has accumulated an investment of approximately 51.4192 million yuan. This product is expected to become the first Category 1.1 Traditional Chinese Medicine specifically for pediatric constipation. The acceptance of the drug review will not have a significant impact on the company's current performance"
datetime: "2025-07-07T07:35:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247445687.md)
  - [en](https://longbridge.com/en/news/247445687.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247445687.md)
generator: "portal-rs"
---

# JUMPCAN: Received the acceptance notice for the pediatric constipation granules medication

JUMPCAN announced that its wholly-owned subsidiary, Jichuan Co., Ltd., has received the "Acceptance Notice" for the application for marketing authorization of "Children's Bian Tong Granules" issued by the National Medical Products Administration. This drug is classified as Traditional Chinese Medicine Category 1.1 and is used for pediatric constipation, with the prescription having applied for a patent. Currently, there are no drugs with the same prescription listed or registered in China. The project has accumulated an investment of approximately 51.4192 million yuan. This product is expected to become the first Category 1.1 Traditional Chinese Medicine specifically for pediatric constipation. The acceptance of the drug review will not have a significant impact on the company's current performance

### Related Stocks

- [600566.CN](https://longbridge.com/en/quote/600566.CN.md)

## Related News & Research

- [US limits air defence time slots for tankers sailing through Hormuz, FT reports](https://longbridge.com/en/news/298785213.md)
- [Havas, linked to Louis Hachette director Yannick Bolloré, purchases EUR 5.31 million of Louis Hachette Group shares](https://longbridge.com/en/news/298621675.md)
- [OpenAI launches public beta of its Agents API and opens up its Codex underlying framework.](https://longbridge.com/en/news/298807188.md)
- [METALS-Copper hovers below record high as non-US supply tightness remains in focus](https://longbridge.com/en/news/298394789.md)
- [Guidance for the 2026/27 financial year](https://longbridge.com/en/news/298632463.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**